Locally advanced pancreatic cancer has a median survival ranging from 6 to 24 months, depending on the ability to undergo both local and systemic treatment.[@CR1]^--^[@CR3] In selected cases, distal pancreatectomy with celiac axis resection (DP-CAR) can lead to radical tumor removal in otherwise borderline or unresectable disease.[@CR4]^--^[@CR13] After celiac axis resection, retrograde flow from the superior mesenteric artery via the pancreatoduodenal arcades feeds the pancreatic head and the liver.[@CR14] In addition, some centers apply preoperative hepatic artery embolization (PHAE) in an attempt to improve collateral flow and reduce postoperative (liver) ischemia, although its impact remains unclear.[@CR14],[@CR15]

In a recent systematic review, we have shown that a highly selected group of patients may benefit from DP-CAR. In an analysis of 240 patients, overall survival was 18 months when DP-CAR was combined with (neo-)adjuvant chemotherapy at an acceptable 90-day mortality rate of 3.5%.[@CR14] However, only relatively small studies (median 7 patients) of low-to-moderate quality could be included, covering a 40-year period. The recent uptake of neoadjuvant FOLFIRINOX (folinic acid, fluorouracil, irinotecan, oxaliplatin) may eventually lead to higher down-staging rates for pancreatic cancer, which could increase the application of DP-CAR and improve survival.[@CR3],[@CR16]

More recent reports, originating from the United States and Japan, showed short-term mortality rates between 5 and 14% and median overall survival ranged from 17 to 40 months.[@CR17]^--^[@CR20] However, still only single-center studies exist, with the largest Western series consisting of 30 patients.[@CR17] The purpose of this pan-European study was to assess overall survival and complications after DP-CAR, including the effect of chemotherapy and PHAE, in a relatively large, multicenter cohort.

Methods {#Sec1}
=======

We performed a pan-European retrospective single-arm cohort study on DP-CAR, among centers represented by members of the European-African Hepato-Pancreato-Biliary Association (E-AHPBA). The study protocol, including an analysis framework, was initiated and approved by the E-AHPBA research and scientific committee and made available online.[@CR21] We invited all E-AHPBA members who had performed DP-CAR between January 1, 2000 and May 31, 2016 to participate. The institutional review board at the Academic Medical Center Amsterdam waived the need for ethical review.

Patients and Data Collection {#Sec2}
----------------------------

All participating centers completed an online survey (Google™ Survey, Mountain View, CA) containing questions regarding standards of care and annual volumes for pancreatic surgery. Each center appointed a local study coordinator, responsible for questionnaire completion and data collection. Subsequently, we retrieved all consecutive patients who underwent DP-CAR for pancreatic cancer within the study period. Patients were excluded in case of non-pancreatic carcinoma diagnosis. Each center submitted baseline (sex, age, BMI, ASA classification, surgical history, and tumor characteristics), treatment (neoadjuvant therapy, embolization, operative variables, adjuvant therapy), and outcome data (morbidity, mortality, length of stay, histopathology, and survival) anonymously using predefined online case report forms (CRF). All data were collected and analyzed by the central study coordinators (SK and JH).

Definitions {#Sec3}
-----------

American Joint Committee on Cancer (AJCC) stage, tumor size, and additional organ and vascular involvement (other than pancreas, spleen, celiac axis, or splenic vessels) were based on preoperative imaging (CT or MRI) and postoperative pathology reports.[@CR22] Pre- and postoperative chemotherapy and radiotherapy treatment was recorded, including the use of FOLFIRINOX. PHAE was defined by preoperative intraluminal catheter embolization of the common hepatic artery. The intention to perform DP-CAR versus intraoperative conversion from distal pancreatectomy to DP-CAR was recorded in a separate variable (intended vs. nonintended).

Postoperative complications were scored as major morbidity (grade 3a--4b) based on the Clavien-Dindo classification of surgical complications.[@CR23] The definitions of the International Study Group on Pancreatic Surgery (ISGPS) were used to score postoperative pancreatic fistula, delayed gastric emptying, and post-pancreatectomy hemorrhage.[@CR24]^--^[@CR26] Surgical site infection was defined using the Center for Disease Control and Prevention (CDC) definitions.[@CR27] Ischemic morbidity was defined as an abdominal organ complication caused by surgery-related ischemia.

Resection margins, including transection and circumferential margins, were categorized according to the Royal College of Pathologists definition and were classified as R0 (no residual, distance margin to tumor ≥ 1 mm), R1 (residual tumor, distance margin to tumor \< 1 mm), and R2 (residual tumor, macroscopically positive margin).[@CR28] Complications, readmissions, and mortality were all collected up to 90 days postoperatively. Overall survival was collected based on the last visit to the hospital, follow-up phone calls, or national security registries depending on the country of origin.

Outcomes {#Sec4}
--------

Primary outcome was overall survival. Secondary outcomes were R0 resection margin, lymph node harvest, postoperative mortality, morbidity (including ischemic (liver) morbidity, postoperative pancreatic fistula, delayed gastric emptying, post-pancreatectomy hemorrhage, organ space (abdominal) infection), reinterventions, length of hospital stay, and readmissions.

Statistical Analysis {#Sec5}
--------------------

All statistical analyses were performed using STATA version 14.1 IC (StataCorp LP, College Station, TX). Categorical data are presented as counts and proportions. Continuous data are presented as both mean (standard deviation) and median (interquartile range). All confidence intervals (CI) are 95%, and alpha levels for significance are \< 0.050. The Mann--Whitney *U* test and Fisher's exact test were used to compare continuous or categorical data, respectively. We used Kaplan--Meier curves, stratified by (neo-)adjuvant therapy regimen, to assess overall survival after DP-CAR. We used the log-rank test to determine significant differences in survival. To assess the impact of annual pancreatic surgery case volume, we performed a sensitivity analysis wherein we excluded all centers at or below the median case volume for pancreatoduodenectomy. We performed a univariate screen (*P* \< 0.20) and multivariable analysis to assess potential factors associated with 90-day mortality.

Results {#Sec6}
=======

Of 35 initial responding hospitals, 20 hospitals across 12 European countries fulfilled the eligibility criteria and included 72 patients undergoing DP-CAR between January 1, 2000 and May 31, 2016. After exclusion of three neuroendocrine tumors and one non-Hodgkin lymphoma, 68 patients with exocrine pancreatic cancer remained. All participating hospitals were high-volume pancreatic centers (median of 70 pancreatoduodenectomies \[interquartile range (IQR) 31--88\] per year). The median total case volume for DP-CAR was 3 (IQR 2--5). Of the participating centers, 14 (70%) reported using DP-CAR in case of intraoperatively detected celiac axis tumor involvement and 3 (15%) reported routine use of PHAE.

Baseline and Treatment {#Sec7}
----------------------

Baseline characteristics are described in Table [1](#Tab1){ref-type="table"}. Preoperatively, 15 (22%) patients received neoadjuvant chemotherapy, 19 (28%) patients received neoadjuvant chemoradiotherapy, and 15 (22%) patients received PHAE. A minimally invasive DP-CAR was performed in 2 (2.9%) patients. Vascular resection was performed in 18 (27%) patients and adrenal gland resection in 15 (22%) patients. A total of 9 (13%) patients underwent hepatic artery reconstruction because of insufficient collateral flow via the pancreatoduodenal arcade (Table [2](#Tab2){ref-type="table"}). This included aortae to hepatic artery (*n* = 6), superior mesenteric to hepatic artery (*n* = 2), and gastroduodenal to hepatic artery confluence (*n* = 1) bypasses.Table 1Baseline characteristics(*N* = 68) Baseline Female sex, no. (%)32 (47.1) Age, median (IQR), year60 (52--67)  Mean (SD), year58.9 (10.6) Body-Mass-Index, median (IQR), kg/m^2^24 (22--26.5)  Mean (SD), kg/m^2^24.3 (3.6)ASA-classification, no. (%)  ASA-112 (17.7)  ASA-250 (73.5)  ASA-36 (8.8) Abdominal surgery history ≥ 1, no. (%)21 (32.8)Preoperative tumor characteristics Additional organ involvement\*, no. (%)  Stomach6 (8.8)  Liver1 (1.5)  Kidney3 (4.4)  Adrenal gland5 (7.4) Additional vascular involvement, no. (%)  Hepatic artery8 (11.8)  Superior mesenteric artery7 (10.3)  Portal vein6 (8.8)  Superior mesenteric vein9 (13.2) Preoperative tumor size, median (IQR), mm37 (30--50)  Mean (SD), mm43 (33)  AJCC staging\*\*, no. (%)  T-stage ≥ 362 (95.4)  N-stage \> 020 (29.9)  M-stage \> 01 (1.5)*ASA* American Society of Anesthesiologists\*Other than celiac axis, pancreas, or spleen\*\*Based on the AJCC criteria[@CR22] Table 2Treatment characteristics(*N* = 68)Preoperative Neoadjuvant treatment, no. (%)   Chemotherapy15 (22.1)   Chemoradiotherapy19 (27.9) Preoperative hepatic artery embolization, no. (%)15 (22.1)Operative Intent to perform DP-CAR55 (80.9) Operative time, median (IQR), min328 (244--415)  Mean (SD), min341 (124) Additional organs resected\*, no. (%)  Stomach7 (10.3)  Liver3 (4.4)  Kidney3 (4.4)  Adrenal gland15 (22.1) Additional vessels resected, no. (%)  Right/left hepatic artery1 (1.5)  Superior mesenteric artery1 (1.5)  Portal vein6 (8.8)  Superior mesenteric vein10 (14.7) Vascular reconstruction, no. (%)  Common hepatic artery9 (13.2)  Superior mesenteric artery1 (1.5)  Portal vein6 (8.8)  Superior mesenteric vein3 (4.4) Estimated blood loss, median (IQR), mL500 (350--1300)  Mean (SD), mL922 (893) Blood transfusion for bleeding (\< 72 h), no. (%)20 (31.3)Postoperative Adjuvant treatment, no. (%)  Chemotherapy41 (60.3)  Radiotherapy2 (2.9)  Chemoradiotherapy2 (2.9)\*Other than celiac axis, pancreas, or spleen

Short-term Outcomes {#Sec8}
-------------------

R0 resection was achieved in 36 (55%) cases, with a median lymph node harvest of 22 (IQR 16--30). After surgery, 7 (10%) patients died within 30-days and 11 (16%) patients died within 90 days, all due to complications. Causes of death were related to gastric ischemia (*n* = 3), liver ischemia (*n* = 2), post-pancreatectomy hemorrhage (*n* = 2), pneumonia (*n* = 2), abdominal infection (*n* = 1), and sepsis with multi-organ failure (*n* = 1). Major morbidity occurred in 17 (25%) patients and an ISGPF grade B/C fistula in 14 (21%) patients. Median length of stay was 17 (IQR 11--27) days, with readmission in 9 (14%) patients (Table [3](#Tab3){ref-type="table"}). Between patients who did (*n* = 15) and did not (*n* = 53) receive PHAE, we found similar rates of liver ischemia (19% vs. 20%, *P* \> 0.99) and 90-day mortality (11% vs. 17%, *P* \> 0.99). Reoperations were performed in 10 (14.7%) patients. Reoperations were gastric (wedge) resection for ischemia (*n* = 3), hepatic artery hemorrhage repair (*n* = 2), re-do anastomosis for a hepatic confluence thrombus (*n* = 1) or hemorrhage (*n* = 1), gastrojejunostomy for persistent delayed gastric emptying (*n* = 1), right hemicolectomy for a perforation (*n* = 1), and embolectomy of the right popliteal artery (*n* = 1).Table 3Ninety-day outcomes after DP-CAR(*N* = 68)Outcomes Mortality within 30 days, no. (%)7 (10.3) Mortality within 90 days, no. (%)11 (16.4) Complications within 90 days, no. (%)  Clavien-Dindo 3a--4b17 (25)  Post-pancreatectomy hemorrhage\*, no. (%)6 (8.8)  Liver ischemia12 (17.7)  Abdominal cavity infection, no. (%)4 (5.9)  Pancreatic fistula grade B/C\* no. (%)14 (20.6)  Delayed gastric emptying grade B/C\*, no. (%)11 (17.5)Reinterventions, no. (%) Endoscopic intervention, no. (%)1 (1.6) Radiologic drainage, no. (%)9 (14.5) Reoperation, no. (%)10 (14.7)  Gastric (wedge) resection for ischemia3  Hemorrhage repair2  Re-do vascular anastomosis2  Gastrojejunostomy for DGE1  Repair of metastatic colon perforation1  Peripheral arterial embolectomy1Histopathology Malignant etiology, no. (%)  PDAC62 (91.2)  Invasive IPMN3 (4.4)  Other malignant diagnosis3 (4.4) Tumor size, median (IQR), mm40 (32--50)  Mean (SD), mm44 (23) Resection margin, no. (%)  R036 (54.6)  R128 (42.4)  R22 (3) Lymph nodes harvested, median (IQR), no.22 (16--29.5)  Median (SD), no.25 (15) Lymph node metastasis, no. (%)45 (66.2) Length of hospital say, median (IQR), days16.5 (11--27)  Mean (SD), days20 (14) Unplanned readmission, no. (%)9 (13.9) Overall survival, median (CI), months17 (10--33)*IPMN* intraductal papillary mucinous neoplasm, *PDAC* pancreatic ductal adenocarcinoma\*ISGPS definitions[@CR24]^**--**^[@CR26]

Survival {#Sec9}
--------

Postoperative follow-up time ranged from 0 to 66 months, with a median of 10 months (IQR 4--19). During the follow-up, 40 (59%) patients expired. This was assessed by means of follow-up phone calls (49%), medical record review (41%), or trough social security registry review (10%). Of all patients, 56 (82%) received either neoadjuvant or adjuvant chemotherapy, of which 12 (18%) received at least one cycle of FOLFIRINOX (neoadjuvant and adjuvant therapy characteristics; Supplement 1). Among the 62 patients with pancreatic ductal adenocarcinoma, Kaplan--Meier estimated median overall survival was 18 months (CI 10--37) (Fig. [1](#Fig1){ref-type="fig"}). In this group, 1-year survival was 60% (CI 46--72%) and 2-year survival was 45% (CI 29--59%).Fig. 1Survival curve after DP-CAR for pancreatic ductal adenocarcinoma. Kaplan--Meier survival estimate for 62 patients with pancreatic ductal adenocarcinoma, excluding three patients with invasive IPMN, and three patients with atypical pancreatic carcinomas. Median overall survival was 18 (CI 10--37) months. Vertical bars indicate censored cases and yellow lines indicate the 95% confidence interval (CI)

Sensitivity and Subgroup Analysis {#Sec10}
---------------------------------

The sensitivity analysis indicated a nonsignificant trend towards lower 90-day mortality in centers with an annual pancreatoduodenectomy case volume above the median (70 per year), total DP-CAR volume above 5, and procedure year after 2008 (see Supplement 2). Among all 68 patients, exploratory sub group analyses assessed neoadjuvant and/or adjuvant chemotherapy/chemoradiation versus no (neo-)adjuvant therapy (Supplement 3a), neoadjuvant versus no neoadjuvant chemotherapy/chemoradiation (Supplement 3b), and adjuvant versus no adjuvant chemotherapy/chemoradiation (Supplement 3c). However, the sample sizes became too low to achieve real statistical solidity.

Predicting 90-day Mortality {#Sec11}
---------------------------

Univariable analysis indicated potential predictors for 90-day mortality: mortality and male sex, additional vascular involvement on CT/MRI, no neoadjuvant chemotherapy, nonintended versus intended DP-CAR, and an annual pancreatoduodenectomy volume above the mean. However, except for male sex (odds ratio \[OR\] 9.45, *P* = 0.04), none of these remained significant in multivariable analysis (Supplement 4).

Discussion {#Sec12}
==========

In this largest Western series on DP-CAR to date, we found a median overall survival of 18 months in 62 patients with pancreatic ductal adenocarcinoma involving the celiac axis. We observed considerable 30-day (10%) and 90-day (16%) mortality, without evidence indicating a beneficial effect of PHAE on the need for arterial reconstruction or ischemic complications. We observed a nonsignificant trend for reduced risk of 90-day mortality among high-volume centers.

These survival and morbidity outcomes are comparable to prior evidence, although the 90-day mortality rate was high. Overall survival after DP-CAR in the literature ranges from median 17--20 months in two recent smaller (*n* \< 20) series and one systematic review (*n* = 240) by our group to median 31--35 months in two larger series (*n* \> 25) from Sapporo and Pittsburgh.[@CR14],[@CR17]^--^[@CR20] Overall survival for unresected patients with locally advanced pancreatic cancer (AJCC Stage III) ranges from 7 months in a large population-based study (*n* = 12,981) to 16--21 months with FOLFIRINOX in single-center studies (*n* = 46--70).[@CR1],[@CR29],[@CR30] However, the existing evidence lacks the necessary detailed information to study vascular involvement.

Postoperative mortality rates in the literature range from 5% (4 of 80 patients) in-hospital mortality in the Sapporo cohort to 14% (4 of 30 patients) 90-day mortality in the Pittsburgh cohort.[@CR17],[@CR19] The latter included 11 patients who underwent robot-assisted DP-CAR with 0% 90-day mortality.[@CR17] Major morbidity rates in the published literature range from 10% to more than 25%, but definitions are heterogeneous.[@CR14],[@CR17]^--^[@CR19] The R1 rate (43%) and lymph node positive rate (66%) were comparable to the results from the recent ESPAC-4 trial.[@CR31] Reports on PHAE in the literature remain scarce, with routine use primarily reported by Japanese studies.[@CR14]

Although our study showed no evidence that PHAE leads to fewer ischemic complications, no final conclusions can be drawn. Apart from a lack of power to detect smaller effects, PHAE may have prevented some aborted surgeries when insufficient collateral flow was found before surgery. Moreover, we were unable to study the potentially beneficial effects of embolization of all three celiac axis branches versus the common hepatic artery alone, as described by Cesaretti and colleagues.[@CR32] We also could not assess the impact of preservation or reconstruction of the left gastric artery using the middle colic artery on gastric ischemia, as described by Okada and colleagues.[@CR33] Such techniques can only be adequately studied via prospective registries, such as the Arterial Network, including patients in whom intended DP-CAR was aborted because of insufficient collateral blood flow.[@CR34] Conversely, we found that in 13 (20%) patients, DP-CAR was performed as an extension to distal pancreatectomy in which initially no vascular resection was planned.

In contrast to our expectations, we did not find a significant association between neoadjuvant chemotherapy and improved survival after DP-CAR. However, the recent report from Pittsburgh (*n* = 30), in which the authors describe a 96% neoadjuvant therapy rate and a 35-month median overall survival, suggests an important role for neoadjuvant treatment.[@CR17] As the authors state, neoadjuvant therapy can be given to downstage the tumor but more importantly to enable detection and treatment of occult micrometastatic disease before committing patients to DP-CAR.[@CR17] Now that FOLFIRINOX treatment has become the new standard of care, the benefit of neoadjuvant chemotherapy may increase further.[@CR17],[@CR18],[@CR20] The assessment of vascular involvement on imaging after FOLFIRINOX in pancreatic cancer is unreliable.[@CR35] In our study, seven patients appeared to have SMA involvement, whereas only one patient required a SMA resection.

This study had several limitations. First, we were unable to include a control group, because a comparable sample of unresected patients with celiac axis involvement was unavailable. Second, selection or reporting bias may have occurred through self-selection by centers with favorable experience with DP-CAR. We aimed to limit this effect by giving anonymity to participating centers. Third, although we tried to collect the biggest Western sample to date, our sample size remains limited. Fourth, study design and data collection commenced before the release of the 8th edition of the AJCC staging criteria; therefore, all staging definitions are according to the 7th edition.[@CR22],[@CR36] Finally, even though only (very) high-volume centers were included, the number of DP-CAR procedures per center was very low. We can only speculate that outcomes may improve with higher volumes.

In conclusion, this study showed that DP-CAR with (neo-)adjuvant treatment (82% of the cases) is associated with an acceptable median overall survival of 18 months. Future efforts should be designed to reduce the 90-day mortality to acceptable levels through better patient selection or centralization of treatment.
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